TY - JOUR
T1 - Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy
AU - Citti, Arianna
AU - Boldrini, Renata
AU - Inserra, Alessandro
AU - Alisi, Anna
AU - Pessolano, Rosanna
AU - Mastronuzzi, Angela
AU - Zin, Angelica
AU - De Sio, Luigi
AU - Rosolen, Angelo
AU - Locatelli, Franco
AU - Fruci, Doriana
PY - 2012/7
Y1 - 2012/7
N2 - Expression of multidrug resistance (MDR) proteins is thought to significantly contribute to the different biological/clinical behaviour of soft tissue sarcomas (STS) of various histological types and clinicopathological stages, as they are responsible for active efflux of cytotoxic drugs from tumour cells. We investigated the expression of 3 MDR proteins, i.e., permeability glycoprotein 1 (P-gp), multidrug resistance-associated protein 1 (MRP1) and multidrug resistance 3 (MDR3), in 43 STS specimens from newly-diagnosed paediatric patients, 31 with rhabdomyosarcoma (RMS) and 12 with non-RMS STS. To assess the influence of chemotherapy on STS drug resistance, the number of MDR-associated protein-positive cells was determined in 15 patients on both primary lesions before chemotherapy and on residual tumour after chemotherapy. At least one of the MDR-associated proteins tested was detected in 84% of primary untreated STS specimens. In these specimens, MRP1 was detected in a high percentage (70%) of the cases, followed by MDR3 in 58% and P-gp in 44%. Many specimens showed co-expression of two different MDR proteins. Interestingly, MDR3 was significantly associated with the presence of PAX3/PAX7-FKHR transcripts in RMS (p
AB - Expression of multidrug resistance (MDR) proteins is thought to significantly contribute to the different biological/clinical behaviour of soft tissue sarcomas (STS) of various histological types and clinicopathological stages, as they are responsible for active efflux of cytotoxic drugs from tumour cells. We investigated the expression of 3 MDR proteins, i.e., permeability glycoprotein 1 (P-gp), multidrug resistance-associated protein 1 (MRP1) and multidrug resistance 3 (MDR3), in 43 STS specimens from newly-diagnosed paediatric patients, 31 with rhabdomyosarcoma (RMS) and 12 with non-RMS STS. To assess the influence of chemotherapy on STS drug resistance, the number of MDR-associated protein-positive cells was determined in 15 patients on both primary lesions before chemotherapy and on residual tumour after chemotherapy. At least one of the MDR-associated proteins tested was detected in 84% of primary untreated STS specimens. In these specimens, MRP1 was detected in a high percentage (70%) of the cases, followed by MDR3 in 58% and P-gp in 44%. Many specimens showed co-expression of two different MDR proteins. Interestingly, MDR3 was significantly associated with the presence of PAX3/PAX7-FKHR transcripts in RMS (p
KW - Chemotherapy resistance
KW - Multidrug resistance
KW - Multidrug resistance-associated proteins
KW - Paediatric tumours
KW - Soft tissue sarcomas
UR - http://www.scopus.com/inward/record.url?scp=84862878619&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862878619&partnerID=8YFLogxK
U2 - 10.3892/ijo.2012.1433
DO - 10.3892/ijo.2012.1433
M3 - Article
C2 - 22504834
AN - SCOPUS:84862878619
SN - 1019-6439
VL - 41
SP - 117
EP - 124
JO - International Journal of Oncology
JF - International Journal of Oncology
IS - 1
ER -